Becton, Dickinson and Company reports developments for a global medical technology business organized around medical essentials, connected care, biopharma systems and interventional products. Company news commonly covers fiscal results, guidance, dividends, share repurchases, debt retirement, executive appointments and strategy updates following the completed separation of the Biosciences and Diagnostic Solutions business.
BD updates also include product and customer developments across its care-delivery platforms. Recent themes include the BD® CentroVena One™ Insertion System for central venous catheter placement, BD Pyxis™ Pro medication dispensing technologies, BD Alaris™ Infusion Systems, vascular access products, medication management, patient-safety workflows and partnerships with health systems.
Summary not available.
BD (Becton, Dickinson and Company) has announced a grant of $360,000 to six U.S. free clinics as part of its Point-of-Care, Enhancing Clinical Effectiveness initiative. This program, established in 2017, has supported 27 clinics across 20 states with a total of $2.6 million. The initiative aims to improve health outcomes in underserved communities by providing diagnostic testing capabilities for common health issues, impacting over 16,500 patient visits this year. Collaborating partners include Heart to Heart International and the National Association of Free and Charitable Clinics.
BD (Becton, Dickinson and Company) has launched the BD® Research Cloud, a cloud-based software designed to enhance flow cytometry workflows. This integrated ecosystem aids scientists in optimizing panel design, collaboration, and data analysis across various research fields like immunology and oncology. Developed by the creators of FlowJo™ Software, it streamlines the workflow by connecting instruments to data analysis, enabling more efficient experiments and faster insights. The platform is built on a reliable cloud infrastructure and aims to support future advancements in flow cytometry research.
BD announced the global availability of its new molecular PCR assay for monkeypox virus, developed in collaboration with CerTest Biotec. This assay is intended for research use only and is now accessible worldwide, including in the U.S. BD is also preparing to submit a clinical test for emergency use authorization. The BD MAX™ System, which supports this assay, features rapid nucleic acid extraction and PCR capabilities. The new test aims to enhance monkeypox research amidst the ongoing public health emergency.
LivaNova PLC (NASDAQ: LIVN) announced the appointment of Brooke Story to its Board of Directors, effective September 15, 2022. Story brings over 20 years of experience in medical technology, currently serving as Worldwide President, Integrated Diagnostic Solutions at BD (NYSE: BDX). She previously held leadership roles at Medtronic, enhancing her expertise in the industry. The Board's Chair, William Kozy, emphasized Story's capability in fostering talent and delivering economic value, which is expected to support LivaNova's growth and innovation strategies.
BD (Becton, Dickinson and Company) has launched the BD EffivaxTM Glass Prefillable Syringe, designed in collaboration with leading pharmaceutical firms. This next-generation syringe aims to enhance vaccine manufacturing efficiency by addressing critical aspects such as processability, contamination, and integrity. With about 70% of top biopharmaceutical companies relying on BD, this innovation is set to meet increasing global demand for prefillable syringes, particularly due to the growth in vaccine pipelines. Additionally, BD continues to invest $1.2 billion in enhancing its manufacturing capacity for these products.
BD (Becton, Dickinson and Company) has announced the promotion of Mike Garrison to EVP and President of the Medical segment, and Rick Byrd to EVP and President of the Interventional segment, effective Sept. 6. Both leaders bring extensive experience from their previous roles within the company. Garrison will focus on advancing innovation and portfolio strategy, while Byrd will continue to drive growth and operational excellence in his segment. The decision follows the upcoming departure of Simon Campion, who is leaving for another executive role.
BD (Becton, Dickinson and Company) will present at the Wells Fargo 2022 Healthcare Conference on September 7, 2022, at 12:30 PM Eastern Time. Interested parties can access the live webcast via the BD investor relations website, with a replay available afterwards. BD is a leading global medical technology company focused on enhancing healthcare quality through innovation. With a strong commitment to improving medical discovery and diagnostics, BD operates globally, aiming to tackle pressing health challenges.
Becton, Dickinson and Company (NYSE: BDX) announced on August 22, 2022, the pricing for its Tender Offers to purchase up to $500,000,000 in cash of various senior notes and debentures. The offers include securities due between 2027 and 2050, with specified total consideration amounts, including early tender payments. The early tender date was set for August 19, 2022, with an early settlement date on August 23, 2022. The company aims to enhance financial flexibility through these transactions while ensuring specific limits on the amounts purchased for each series.
Becton, Dickinson and Company (NYSE: BDX) reported early tender results for its debt securities tender offers, announcing an increase in the Offer SubCap for the 3.794% Senior Notes due 2050 from $175 million to $190 million. The company is seeking to purchase up to $500 million in various securities, with significant participation noted by the early tender date of August 19, 2022. Notably, all conditions for the tender offers were satisfied, with payment for accepted securities scheduled for August 23, 2022. The offer details are outlined in the Offer to Purchase.